Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 5/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177940 | 1.00 | TBK1 (0.39) | TBK1IKBKEIRAK4MAPK10PRKDC | |
| SCHEMBL22635848 | 0.84 | IRAK4 (0.38) | TBK1IKBKEIRAK4PRKDCSYK | |
| SCHEMBL21187357 | 0.84 | IRAK4 (0.38) | TBK1IKBKEIRAK4PRKDCSYK | |
| SCHEMBL21187294 | 0.84 | TBK1 (0.39) | TBK1IKBKEIRAK4EHMT2EHMT1 | |
| SCHEMBL21179460 | 0.84 | TBK1 (0.39) | TBK1IKBKEIRAK4EHMT2EHMT1 | |
| SCHEMBL22651998 | 0.84 | PRKDC (0.38) | TBK1IRAK4PRKDCKCNH2CCNC | |
| SCHEMBL17750585 | 0.83 | TBK1 (0.42) | TBK1IKBKEMAPK10SYKTTK | |
| SCHEMBL21182358 | 0.83 | HRH4 (0.43) | TBK1IKBKEIRAK4EHMT2EHMT1 | |
| SCHEMBL21178253 | 0.82 | CCNC (0.37) | TBK1IKBKEIRAK4PRKDCSYK | |
| SCHEMBL21187290 | 0.82 | CCNC (0.37) | TBK1IKBKEIRAK4PRKDCSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TBK1 475/4885IKBKE 490/4885IRAK4 1175/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | TBK1 475/4885IKBKE 490/4885IRAK4 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.